There’s an intriguing growth story in China right now that you need to be following — particularly one specific play that could help you take advantage of a powerful new trend before it catches fire. This growth market is so compelling, in fact, that it’s making me rethink my long-standing prohibition on Chinese ADRs. But …read more
Why Investors Flock to the Penny Sleuth...
The Penny Sleuth is your independent, in-depth, unbiased source on penny stocks, options, microcaps, pink sheet stocks, the OTCBB and securities. In our e-letter you’ll find analysis on some of the smallest, fastest moving growth stocks on the market.
It’s all we do — even though the mainstream financial media avoid these stocks like the plague. The Penny Sleuth teams makes sure you are the first to know about any opportunity, no matter what the industry or market. We scour all types of investments — everything from new technologies and biotech discoveries to groundbreaking energy companies and commodities.
We don’t accept compensation for our coverage of these companies — we aren’t in the investor relations business. Great investment ideas are our forte, but we aren’t financial advisers. If you need personal investment advice, contact your broker. Also, we don’t own any positions — long or short — in any of the stocks we recommend in any of our trading services. And we make it a point to disclose our ownership in companies we mention in any of our Penny Sleuth columns.
Sign up for the FREE Penny Sleuth e-letter and receive issues delivered straight to your inbox!
It is becoming more and more difficult for me to deny the rally we are now witnessing. The market is melting up right before our very eyes. Bears will try to explain away the 5%-plus move in the S&P so far this year as a fluke or a temporary reaction ...read more
The idea of betting big on a hot new IPO in the hopes of making a buck is quickly losing credibility. And it soon might get much, much worse. Facebook — and it’s massive, impending stock offering — could be the nail in the coffin for social media stocks if ...read more
Economists expected US GDP to expand by a 3% annual rate during the fourth quarter. It didn’t — instead expanding at a 2.8% clip. Traders immediately sold futures, only to buy back stocks an hour later when the market opened. We should continue to expect this tug-of-war between bulls and bears ...read more
When you spend your days dissecting countless stocks, you sometimes stumble upon small groups of similar companies having their own private bull market. Often, the momentum can be traced back to an obvious catalyst — fundamental improvements within the group or a well-publicized buyout in the sector. But sometimes, investors and ...read more
I have to confess that I tend to find banking somewhat boring — at least compared with the subject of the transformational technologies that I normally write about. From my perspective, banking stocks lack the exciting potential of biotech companies working on a cure for cancer or semiconductor plays pushing ...read more
Investor uncertainty about Europe’s massive debt debacle is on the verge of dragging down the financial sector. Today, I want to show you why Europe still remains a threat — even though Wall Street seems to have forgotten about it — and how you can make one single move to ...read more
This is probably my favorite special situation of all for its simplicity. Joel Greenblatt wrote about it in his 1997 book You Can Be a Stock Market Genius. Greenblatt, at that time, was a relative unknown. But his Gotham Capital had put up 50% average annual returns for 10 years. The ...read more
The business of medical biotechnologies operates within an extraordinarily complex regulatory system. The SEC and the IRS are only the beginning of the story... In the United States, the Food and Drug Administration determines what can legally be sold. It even exercises control over what can be said by companies about medical ...read more
